Eckert & Ziegler SE Secures Good Manufacturing Practice Certification for Actinium‑225 Production

On 28 October 2026, Eckert & Ziegler SE, the German health‑care equipment manufacturer headquartered in Berlin, announced that it has obtained a Good Manufacturing Practice (GMP) certification for the production of the radioactive isotope Actinium‑225 (Ac‑225). The approval was granted by the German regulatory authority after a thorough review of the company’s production processes and quality controls.

Significance of Actinium‑225

Actinium‑225 is a short‑lived alpha‑emitting radioisotope that has emerged as a promising agent for targeted radionuclide therapy. Its high energy and favorable decay properties make it effective against solid tumours, including certain types of prostate and breast cancer, as well as malignant lymphomas. In recent years, the demand for high‑purity Ac‑225 has surged, driven by advances in radiopharmaceutical development and the expansion of clinical trials worldwide.

Eckert & Ziegler’s expertise lies in designing and calibrating specialised equipment for the pharmaceutical sector, such as gamma cameras and positron emission tomography (PET) scanners. The company’s new GMP‑certified Ac‑225 production capability extends this portfolio into the therapeutic arena, allowing it to supply a critical raw material for oncology research and treatment.

Regulatory Milestone

The GMP certification confirms that Eckert & Ziegler’s manufacturing facilities comply with the stringent quality standards set by the European Medicines Agency and the German Federal Institute for Drugs and Medical Devices (BfArM). The certification covers all stages of the Ac‑225 production chain—from raw material handling and isotope synthesis to final product testing and release.

The approval also reflects the company’s commitment to patient safety and product reliability. By meeting GMP requirements, Eckert & Ziegler can participate in clinical trials and potentially commercialise Ac‑225‑based therapeutics, positioning itself as a key supplier in a rapidly growing niche of nuclear medicine.

Market Impact

Following the announcement, Eckert & Ziegler’s shares traded on the Xetra exchange at a close of €12.99 on 26 October 2026, slightly above the 52‑week low of €11.91 and within 5 % of the 52‑week high of €17.47. Market analysts noted that the certification could enhance the company’s valuation, particularly as the global market for radioisotopes is projected to expand at a compound annual growth rate exceeding 7 % over the next decade.

The company’s market capitalisation stands at approximately €812 million, with a price‑earnings ratio of 16.34. The certification is expected to reinforce investor confidence, especially as the broader technology and science indices (TecDAX and SDAX) recorded modest gains during the trading session.

Outlook

Eckert & Ziegler’s entry into Ac‑225 production is a strategic step toward diversifying its product range and capturing a share of the burgeoning nuclear‑therapeutics market. The company’s established manufacturing infrastructure, combined with its GMP certification, should facilitate collaboration with pharmaceutical developers seeking reliable isotope supply for pre‑clinical and clinical studies.

While the immediate market reaction remains muted, the long‑term implications for Eckert & Ziegler SE suggest a positive trajectory as the demand for precision radiopharmaceuticals continues to rise.